NCI-2023-04004

A GLOBAL, PHASE 3, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF FURMONERTINIB COMPARED TO PLATINUM-BASED CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH EPIDERMAL GROWTH FACTOR RECEPTOR EXON 20 INSERTION MUTATIONS

This is a large Phase 3 study happening in multiple locations worldwide. It aims to compare the effectiveness and safety of a drug called furmonertinib with platinum-based chemotherapy as the first treatment for patients with advanced or metastatic non-small cell lung cancer (NSCLC) who have a specific genetic mutation called epidermal growth factor receptor exon 20 insertion. The study is open-label, meaning participants and researchers will know which treatment each person receives. The goal is to see if furmonertinib works better than chemotherapy for this type of lung cancer.

Phase 3: A phase 3 clinical trial is a large-scale study designed to assess the effectiveness and safety of a new medical treatment or approach compared to a standard treatment

small cell lung cancer (SCLC): A type of lung cancer with small cells that grow too much and can spread to other parts of the body

mutation: Mutation is an alteration in the genetic material of a cell or a virus that can be inherited by its descendants

epidermal growth factor receptor: Epidermal Growth Factor Receptor (EGFR) is on the surface of cells and helps them grow and divide. In cancer, EGFR is like a switch that gets stuck in the "on" position, making cells grow and divide too much.

open-label: Patients know which treatments are being given to them

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT05607550

Clinical Trial Site: Einstein

To see all available clinical trials click here.